ticlopidine has been researched along with Ischemia in 92 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "The Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial was a randomized, blinded, multicenter, trial of 19,185 patients with atherosclerotic disease manifested as recent ischemic stroke or myocardial infarction or symptomatic peripheral arterial disease." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "A significant number of ischemic events occur after acute myocardial infarction (MI), even when adhering to dual antiplatelet therapy including aspirin and clopidogrel." | 7.91 | The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction . ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2019) |
| "Clopidogrel is an antiplatelet drug primarily used to treat or prevent acute ischemic stroke (IS) or myocardial infarction (MI)." | 7.83 | Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( Cheng, W; Chi, L; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2016) |
| "We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)." | 7.80 | Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014) |
| "Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI." | 7.78 | Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012) |
| " In this study, we aimed to assess the effects of clopidogrel, an antithrombotic agent, on experimental ischemia-reperfusion model in rats." | 7.73 | Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. ( Akbas, MH; Berki, KT; Bulbul, S; Kanko, M; Maral, H; Omay, O; Ozden, M; Yavuz, S, 2005) |
| "The EUCLID trial investigated the effect of monotherapy with ticagrelor versus clopidogrel in 13,885 patients with peripheral artery disease (PAD); the primary endpoint was cardiovascular death, myocardial infarction, or ischaemic stroke." | 5.27 | Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. ( Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)." | 5.14 | Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010) |
| "The Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial was a randomized, blinded, multicenter, trial of 19,185 patients with atherosclerotic disease manifested as recent ischemic stroke or myocardial infarction or symptomatic peripheral arterial disease." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to prevent recurrent ischemic event occurrence in coronary artery disease patients." | 4.89 | Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. ( Gurbel, PA; Tantry, US, 2013) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| " The benefits in mortality and reinfarction were driven by the treatment with prasugrel or ticagrelor, without a significant difference in terms of major bleeding complications as compared to standard-dose clopidogrel (5% vs." | 4.87 | Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. ( Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M, 2011) |
| "Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine." | 4.85 | Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009) |
| "To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin." | 4.84 | Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008) |
| " For patients with disabling intermittent claudication who do not respond to conservative measures and who are not candidates for surgical or catheter-based intervention, we suggest cilostazol (Grade 2A)." | 4.82 | Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004) |
| "A significant number of ischemic events occur after acute myocardial infarction (MI), even when adhering to dual antiplatelet therapy including aspirin and clopidogrel." | 3.91 | The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction . ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2019) |
| "Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited." | 3.85 | Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry. ( Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I, 2017) |
| "Clopidogrel is an antiplatelet drug primarily used to treat or prevent acute ischemic stroke (IS) or myocardial infarction (MI)." | 3.83 | Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( Cheng, W; Chi, L; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2016) |
| "This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease." | 3.81 | Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015) |
| "In a novel application, we prospectively monitored ischemic, bleeding, and mortality outcomes among patients initiating prasugrel versus clopidogrel in routine care during the first 2 years following the approval of prasugrel." | 3.80 | Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. ( Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G, 2014) |
| "We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA)." | 3.80 | Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy. ( Chai, HT; Chang, HW; Chen, CH; Chen, YC; Chen, YL; Chua, S; Chung, SY; Ko, SF; Leu, S; Lin, PY; Sheu, JJ; Sung, PH; Tsai, TH; Yip, HK, 2014) |
| " Patients with critical limb ischemia following stent thrombosis were included if dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel per day had been administered over three months prior to enrollment." | 3.80 | Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. ( Baecker, C; Baro, D; Meybohm, P; Mutlak, H; Schmitz-Rixen, T; Wand, S; Weber, CF; Zacharowski, K, 2014) |
| " This study evaluated the results of infrainguinal endovascular procedures performed for critical ischemia, in accordance with patient compliance to clopidogrel treatment." | 3.79 | Platelet antiaggregation therapy and subinguinal endovascular revascularization. ( Aleil, B; Chakfe, N; Geny, B; Kretz, JG; Lejay, A; Stephan, D; Thaveau, F, 2013) |
| "Ninety-minute ischemia before vein grafting can cause serious EC loss, but does not increase early intimal hyperplasia when clopidogrel is administered." | 3.78 | Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting. ( Guo, Q; Lu, Z; Sun, M; Zou, R, 2012) |
| "Combined cilostazol-clopidogrel therapy is superior to either agent alone in improving ischemia in rodent CLI." | 3.78 | Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. ( Chang, HW; Chen, YL; Chua, S; Leu, S; Lin, KC; Sheu, JJ; Sun, CK; Tsai, CY; Tsai, TH; Yang, JL; Yen, CH; Yip, HK, 2012) |
| "Clopidogrel responsiveness has been proposed to be involved in recurrent ischemic events after stenting for non-ST elevation acute coronary syndromes (NSTE ACS)." | 3.74 | ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin, L; Carvajal, J; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2007) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| " In this study, we aimed to assess the effects of clopidogrel, an antithrombotic agent, on experimental ischemia-reperfusion model in rats." | 3.73 | Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. ( Akbas, MH; Berki, KT; Bulbul, S; Kanko, M; Maral, H; Omay, O; Ozden, M; Yavuz, S, 2005) |
| "To assess the effect of ticlopidine on the cutaneous circulation, 25 patients with lower limb ischemia were investigated just before and at two hours after being given a 200 mg oral dose of ticlopidine." | 3.68 | Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease. ( Iwai, T; Qian, S, 1993) |
| "Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events." | 2.84 | Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2017) |
| "Twenty patients with ≥50 % angiographic stenosis of the SFA had blood drawn just proximal to the lesion and from a contralateral site free of disease." | 2.78 | Increased local cytokine production at culprit superficial femoral artery plaques. ( Adams, JE; Ashikaga, T; Bertges, DJ; Dauerman, HL; Donaldson, CW; Elgharib, NZ; Mueller, EL; Prabhu, W; Schneider, DJ, 2013) |
| "Between June 2008 and May 2009, 88 consecutive patients referred for EVT were randomly divided into a clopidogrel group (42 cases) and a clopidogrel combined with warfarin group (46 cases) before the procedure." | 2.78 | A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery. ( Feng, Y; Guo, M; Li, H; Liang, G; Luo, X; Zhang, C; Zhang, F, 2013) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| " The comparator was standard dosage of clopidogrel." | 2.49 | Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. ( Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A, 2013) |
| "Fundamentally, acute coronary syndromes are platelet-centric diseases, resulting from platelet-rich thrombi that develop at the site of vessel wall injury." | 2.44 | The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. ( Gurbel, PA; Tantry, US, 2008) |
| "Atherothrombosis is a generalized and progressive process with an inflammatory component." | 2.44 | Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. ( Ellahham, S, 2008) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| "We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0." | 1.38 | Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012) |
| "We report a case of spontaneous spinal epidural hematoma (SSEH) in a 60-yr-old woman who was treated with clopidogrel for frequent transient ischemic attacks." | 1.34 | Clopidogrel-induced spontaneous spinal epidural hematoma. ( Hong, JT; Lee, SW; Son, BC; Sung, JH, 2007) |
| "Ten patients with traumatic dissection underwent stenting." | 1.33 | Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections. ( Ben-Hur, T; Cohen, JE; Gomori, JM; Rajz, G; Umansky, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.26) | 18.7374 |
| 1990's | 6 (6.52) | 18.2507 |
| 2000's | 30 (32.61) | 29.6817 |
| 2010's | 52 (56.52) | 24.3611 |
| 2020's | 1 (1.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, S | 1 |
| Gul, S | 1 |
| Siraj, S | 1 |
| Hussain, A | 1 |
| Sheikh, FS | 1 |
| Shah, SU | 1 |
| Janjua, K | 1 |
| Khan, H | 1 |
| Hamdard, MH | 1 |
| Qiao, M | 1 |
| Bi, Q | 1 |
| Fu, P | 1 |
| Wang, Y | 2 |
| Song, Z | 1 |
| Guo, F | 1 |
| Xanthopoulou, I | 1 |
| Davlouros, P | 1 |
| Deftereos, S | 1 |
| Hamilos, M | 1 |
| Sitafidis, G | 1 |
| Kanakakis, I | 1 |
| Vavouranakis, M | 1 |
| Goudevenos, J | 1 |
| Lekakis, J | 1 |
| Alexopoulos, D | 1 |
| Norgren, L | 2 |
| Patel, MR | 2 |
| Hiatt, WR | 2 |
| Wojdyla, DM | 1 |
| Fowkes, FGR | 1 |
| Baumgartner, I | 2 |
| Mahaffey, KW | 2 |
| Berger, JS | 2 |
| Jones, WS | 2 |
| Katona, BG | 2 |
| Held, P | 2 |
| Blomster, JI | 1 |
| Rockhold, FW | 1 |
| Björck, M | 1 |
| Bath, PM | 1 |
| Woodhouse, LJ | 1 |
| Appleton, JP | 1 |
| Beridze, M | 1 |
| Christensen, H | 1 |
| Dineen, RA | 1 |
| Duley, L | 1 |
| England, TJ | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| James, M | 1 |
| Krishnan, K | 1 |
| Markus, HS | 1 |
| Montgomery, AA | 1 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Ranta, A | 1 |
| Robinson, TG | 1 |
| Scutt, P | 1 |
| Venables, GS | 1 |
| Sprigg, N | 1 |
| Johnston, SC | 2 |
| Easton, JD | 2 |
| Farrant, M | 1 |
| Barsan, W | 1 |
| Conwit, RA | 1 |
| Elm, JJ | 1 |
| Kim, AS | 1 |
| Lindblad, AS | 1 |
| Palesch, YY | 1 |
| Lewis, SR | 1 |
| Pritchard, MW | 1 |
| Schofield-Robinson, OJ | 1 |
| Alderson, P | 1 |
| Smith, AF | 1 |
| Pavlovic, M | 1 |
| Apostolovic, S | 1 |
| Stokanovic, D | 1 |
| Lilic, J | 1 |
| Konstantinovic, SS | 1 |
| Zvezdanovic, JB | 1 |
| Nikolic, VN | 1 |
| Lejay, A | 1 |
| Thaveau, F | 1 |
| Aleil, B | 1 |
| Geny, B | 1 |
| Kretz, JG | 1 |
| Stephan, D | 1 |
| Chakfe, N | 1 |
| Li, H | 1 |
| Zhang, F | 1 |
| Liang, G | 1 |
| Luo, X | 1 |
| Zhang, C | 1 |
| Feng, Y | 1 |
| Guo, M | 1 |
| Bennett, D | 1 |
| Yan, B | 1 |
| Siller-Matula, JM | 1 |
| Jilma, B | 1 |
| Gagne, JJ | 1 |
| Rassen, JA | 1 |
| Choudhry, NK | 1 |
| Bohn, RL | 1 |
| Patrick, AR | 1 |
| Sridhar, G | 1 |
| Daniel, GW | 1 |
| Liu, J | 1 |
| Schneeweiss, S | 1 |
| Sheu, JJ | 2 |
| Lin, PY | 1 |
| Sung, PH | 1 |
| Chen, YC | 1 |
| Leu, S | 2 |
| Chen, YL | 2 |
| Tsai, TH | 2 |
| Chai, HT | 1 |
| Chua, S | 2 |
| Chang, HW | 2 |
| Chung, SY | 1 |
| Chen, CH | 1 |
| Ko, SF | 1 |
| Yip, HK | 2 |
| Spiliopoulos, S | 1 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Koch, GG | 1 |
| Polzin, A | 2 |
| Schleicher, M | 1 |
| Seidel, H | 1 |
| Scharf, RE | 1 |
| Merx, MW | 1 |
| Kelm, M | 2 |
| Zeus, T | 2 |
| Wand, S | 1 |
| Baro, D | 1 |
| Baecker, C | 1 |
| Meybohm, P | 1 |
| Schmitz-Rixen, T | 1 |
| Zacharowski, K | 1 |
| Mutlak, H | 1 |
| Weber, CF | 1 |
| Sun, B | 1 |
| Li, J | 1 |
| Dong, M | 1 |
| Yang, L | 1 |
| Wu, C | 1 |
| Zhu, L | 1 |
| Cong, YL | 1 |
| Armstrong, EJ | 1 |
| Anderson, DR | 1 |
| Yeo, KK | 1 |
| Singh, GD | 1 |
| Bang, H | 1 |
| Amsterdam, EA | 1 |
| Freischlag, JA | 1 |
| Laird, JR | 1 |
| Afzal, S | 1 |
| Balzer, J | 1 |
| Rassaf, T | 1 |
| Yi, X | 1 |
| Lin, J | 1 |
| Zhou, Q | 1 |
| Wang, C | 1 |
| Cheng, W | 1 |
| Chi, L | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Zeller, T | 1 |
| Domanski, MJ | 1 |
| Zhao, Z | 1 |
| Li, X | 1 |
| Sun, S | 1 |
| Mei, S | 1 |
| Ma, N | 1 |
| Miao, Z | 1 |
| Zhao, M | 1 |
| Peng, S | 1 |
| Fichter, AM | 1 |
| Ritschl, LM | 1 |
| Robitzky, LK | 1 |
| Wagenpfeil, S | 1 |
| Mitchell, DA | 1 |
| Wolff, KD | 1 |
| Mücke, T | 1 |
| Fowkes, FG | 1 |
| Heizer, G | 1 |
| Blomster, J | 1 |
| Millegård, M | 1 |
| Reist, C | 1 |
| Thott, O | 1 |
| Granath, F | 1 |
| Malmstedt, J | 1 |
| Wahlgren, CM | 1 |
| Zimmermann, N | 1 |
| Hohlfeld, T | 1 |
| Gurbel, PA | 2 |
| Tantry, US | 2 |
| Price, MJ | 1 |
| Mohler, ER | 1 |
| Angiolillo, DJ | 1 |
| Suryadevara, S | 1 |
| Raynaud, A | 1 |
| Novelli, L | 1 |
| Rovani, X | 1 |
| Carreres, T | 1 |
| Bourquelot, P | 1 |
| Hermelin, A | 1 |
| Angel, C | 1 |
| Beyssen, B | 1 |
| Collet, JP | 1 |
| Montalescot, G | 3 |
| Nikolsky, E | 1 |
| Stone, GW | 1 |
| Kirtane, AJ | 1 |
| Dangas, GD | 1 |
| Lansky, AJ | 1 |
| McLaurin, B | 1 |
| Lincoff, AM | 2 |
| Feit, F | 1 |
| Moses, JW | 1 |
| Fahy, M | 1 |
| Manoukian, SV | 1 |
| White, HD | 1 |
| Ohman, EM | 1 |
| Bertrand, ME | 1 |
| Cox, DA | 1 |
| Mehran, R | 1 |
| Dedaj, R | 1 |
| Levy, W | 1 |
| Tacke, J | 1 |
| Lindhoff-Last, E | 1 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 1 |
| Adams, HP | 1 |
| Burdess, A | 2 |
| Nimmo, AF | 2 |
| Garden, OJ | 2 |
| Murie, JA | 2 |
| Dawson, AR | 2 |
| Fox, KA | 4 |
| Newby, DE | 2 |
| Breet, NJ | 1 |
| VAN Werkum, JW | 1 |
| Bouman, HJ | 1 |
| Kelder, JC | 1 |
| Ten Berg, JM | 1 |
| Hackeng, CM | 1 |
| Hwang, SJ | 1 |
| Jeong, YH | 1 |
| Kim, IS | 1 |
| Park, KS | 1 |
| Kang, MK | 1 |
| Koh, JS | 1 |
| Park, JR | 1 |
| Park, Y | 1 |
| Koh, EH | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Kim, S | 1 |
| Conrad, MF | 1 |
| Crawford, RS | 1 |
| Hackney, LA | 1 |
| Paruchuri, V | 1 |
| Abularrage, CJ | 1 |
| Patel, VI | 1 |
| Lamuraglia, GM | 1 |
| Cambria, RP | 1 |
| Morofuji, Y | 1 |
| So, G | 1 |
| Hiu, T | 1 |
| Kawakubo, J | 1 |
| Hayashi, K | 1 |
| Kitagawa, N | 1 |
| Morikawa, M | 1 |
| Suyama, K | 1 |
| Nagata, I | 1 |
| Navarese, EP | 1 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Suriano, P | 1 |
| Kozinski, M | 1 |
| Castriota, F | 1 |
| De Servi, S | 1 |
| Kubica, J | 1 |
| De Luca, G | 1 |
| Zhang, HL | 1 |
| Chen, XB | 1 |
| Fan, ZY | 1 |
| Wu, J | 1 |
| Kwon, SU | 1 |
| Hong, KS | 1 |
| Kang, DW | 1 |
| Park, JM | 1 |
| Lee, JH | 1 |
| Cho, YJ | 1 |
| Yu, KH | 1 |
| Koo, JS | 1 |
| Wong, KS | 1 |
| Lee, SH | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Jeong, SW | 1 |
| Bae, HJ | 1 |
| Lee, BC | 1 |
| Han, MK | 1 |
| Rha, JH | 1 |
| Kim, HY | 1 |
| Mok, VC | 1 |
| Lee, YS | 1 |
| Kim, GM | 1 |
| Suwanwela, NC | 1 |
| Yun, SC | 1 |
| Nah, HW | 1 |
| Kim, JS | 1 |
| Aw, D | 1 |
| Sharma, JC | 1 |
| Meves, SH | 1 |
| Overbeck, U | 1 |
| Endres, HG | 1 |
| Krogias, C | 1 |
| Neubauer, H | 1 |
| Bhatt, DL | 5 |
| Paré, G | 1 |
| Eikelboom, JW | 1 |
| Simonsen, KL | 1 |
| Emison, ES | 1 |
| Steg, PG | 2 |
| Bhakta, N | 1 |
| Hacke, W | 4 |
| Flather, MD | 2 |
| Mak, KH | 2 |
| Cacoub, P | 2 |
| Creager, MA | 2 |
| Berger, PB | 2 |
| Steinhubl, SR | 2 |
| Murugesan, G | 1 |
| Mehta, SR | 1 |
| Kottke-Marchant, K | 1 |
| Topol, EJ | 4 |
| Sheikh-Taha, M | 1 |
| Ghosn, S | 1 |
| Lin, KC | 1 |
| Tsai, CY | 1 |
| Yen, CH | 1 |
| Sun, CK | 1 |
| Yang, JL | 1 |
| Meade, T | 1 |
| Zou, R | 1 |
| Sun, M | 1 |
| Lu, Z | 1 |
| Guo, Q | 1 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Chatterjee, S | 1 |
| Ghose, A | 1 |
| Sharma, A | 1 |
| Guha, G | 1 |
| Mukherjee, D | 1 |
| Frankel, R | 1 |
| Donaldson, CW | 1 |
| Schneider, DJ | 1 |
| Bertges, DJ | 1 |
| Adams, JE | 1 |
| Elgharib, NZ | 1 |
| Mueller, EL | 1 |
| Prabhu, W | 1 |
| Ashikaga, T | 1 |
| Dauerman, HL | 1 |
| Avegliano, G | 1 |
| Evangelista, A | 1 |
| Elorz, C | 1 |
| González-Alujas, T | 1 |
| García del Castillo, H | 1 |
| Soler-Soler, J | 1 |
| Rao, U | 1 |
| Weston, C | 1 |
| Clagett, GP | 1 |
| Sobel, M | 1 |
| Jackson, MR | 1 |
| Lip, GY | 1 |
| Tangelder, M | 1 |
| Verhaeghe, R | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Kanko, M | 1 |
| Maral, H | 1 |
| Akbas, MH | 1 |
| Ozden, M | 1 |
| Bulbul, S | 1 |
| Omay, O | 1 |
| Yavuz, S | 1 |
| Berki, KT | 1 |
| Cohen, JE | 1 |
| Ben-Hur, T | 1 |
| Rajz, G | 1 |
| Umansky, F | 1 |
| Gomori, JM | 1 |
| Ziegler, S | 1 |
| Schillinger, M | 1 |
| Funk, M | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Mlekusch, W | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Minar, E | 1 |
| Brunner, M | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Vinholt, P | 1 |
| Poulsen, TS | 1 |
| Korsholm, L | 1 |
| Kristensen, SR | 1 |
| Hallas, J | 1 |
| Damkier, P | 1 |
| Mickley, H | 1 |
| Black, HR | 1 |
| Boden, WE | 1 |
| Cohen, EA | 1 |
| Haffner, SM | 1 |
| Hamm, CW | 1 |
| Hankey, GJ | 1 |
| Mas, JL | 1 |
| Pearson, TA | 1 |
| Weber, MA | 1 |
| Booth, J | 1 |
| Norris, JW | 1 |
| Barnett, HJ | 1 |
| Collins, P | 1 |
| Ford, I | 1 |
| Greaves, M | 1 |
| Macaulay, E | 1 |
| Brittenden, J | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Sung, JH | 1 |
| Hong, JT | 1 |
| Son, BC | 1 |
| Lee, SW | 1 |
| Frere, C | 1 |
| Cuisset, T | 1 |
| Quilici, J | 1 |
| Camoin, L | 1 |
| Carvajal, J | 1 |
| Morange, PE | 1 |
| Lambert, M | 1 |
| Juhan-Vague, I | 1 |
| Bonnet, JL | 1 |
| Alessi, MC | 1 |
| Ellahham, S | 1 |
| Andreozzi, GM | 1 |
| Arosio, E | 1 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Hermosillo, AJ | 1 |
| Spinler, SA | 1 |
| Katsumura, T | 2 |
| Mishima, Y | 1 |
| Kamiya, K | 1 |
| Sakaguchi, S | 1 |
| Tanabe, T | 1 |
| Sakuma, A | 1 |
| Qian, S | 1 |
| Iwai, T | 1 |
| Born, GV | 1 |
| Collins, R | 1 |
| Dippel, DW | 1 |
| D'Sa, S | 1 |
| Machin, SJ | 1 |
| Watson, HR | 1 |
| Belcher, G | 1 |
| Horrocks, M | 1 |
| Kobza, II | 1 |
| Hirsch, AT | 2 |
| Ringleb, PA | 2 |
| Chew, DP | 1 |
| Gusak, VK | 1 |
| Shtutin, AA | 1 |
| Rodin, IuV | 1 |
| Il'iushchenko, SV | 1 |
| Iurchuk, AIu | 1 |
| Undas, A | 1 |
| Bazan-Socha, S | 1 |
| Swadzba, J | 1 |
| Musial, J | 1 |
| Lièvre, M | 1 |
| Chirossel, P | 1 |
| Adenis, T | 1 |
| Amiel, M | 1 |
| Boissel, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822] | Phase 3 | 13,885 participants (Actual) | Interventional | 2012-12-04 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study[NCT01968499] | 1,805 participants (Actual) | Observational [Patient Registry] | 2011-03-31 | Completed | |||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention[NCT01012193] | Phase 4 | 134 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039] | Phase 4 | 457 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361] | 159 participants (Actual) | Observational | 2010-07-31 | Completed | |||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 117 |
| Clopidogrel 75 mg od | 115 |
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 628 |
| Clopidogrel 75 mg od | 635 |
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 179 |
| Clopidogrel 75 mg od | 208 |
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1211 |
| Clopidogrel 75 mg od | 1250 |
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg bd | 751 |
| Clopidogrel 75 mg od | 740 |
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 766 |
| Clopidogrel 75 mg od | 759 |
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 839 |
| Clopidogrel 75 mg od | 833 |
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 363 |
| Clopidogrel 75 mg od | 343 |
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1312 |
| Clopidogrel 75 mg od | 1314 |
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 846 |
| Clopidogrel 75 mg od | 892 |
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 100 |
| Clopidogrel 75 mg od | 116 |
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 349 |
| Clopidogrel 75 mg od | 334 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1119 |
| Clopidogrel 75 mg od | 1140 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1183 |
| Clopidogrel 75 mg od | 1199 |
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 983 |
| Clopidogrel 75 mg od | 992 |
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 789 |
| Clopidogrel 75 mg od | 786 |
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 250 |
| Clopidogrel 75 mg od | 272 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 206 |
| Clopidogrel 75 mg od | 188 |
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 168 |
| Clopidogrel 75 mg od | 112 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 113 |
| Clopidogrel 75 mg od | 109 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 193 |
| Clopidogrel 75 mg od | 175 |
"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Change in ABI/TBI (Mean) | |||
|---|---|---|---|---|
| ABI - 6 months N = 6184(Tica), 6319(Clopi) | ABI - End of treatment N = 4951(Tica), 5073(Clopi) | TBI - 6 months N = 55(Tica), 48(Clopi) | TBI - End of treatment N = 36(Tica), 21(Clopi) | |
| Clopidogrel 75 mg od | 0.011 | 0.016 | 0.036 | -0.065 |
| Ticagrelor 90 mg bd | 0.016 | 0.022 | 0.050 | 0.059 |
"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | |||||
|---|---|---|---|---|---|---|
| Stage I - End of treatment | Stage IIa - End of treatment | Stage IIb - End of treatment | Stage III - End of treatment | Stage IV - End of treatment | Missing - End of treatment | |
| Clopidogrel - Stage I | 743 | 230 | 56 | 9 | 4 | 250 |
| Clopidogrel - Stage IIa | 723 | 1956 | 311 | 15 | 7 | 724 |
| Clopidogrel - Stage IIb | 198 | 557 | 450 | 23 | 10 | 370 |
| Clopidogrel - Stage III | 33 | 33 | 38 | 23 | 5 | 60 |
| Clopidogrel - Stage IV | 19 | 21 | 15 | 12 | 13 | 45 |
| Ticagrelor - Stage I | 775 | 227 | 45 | 7 | 7 | 248 |
| Ticagrelor - Stage IIa | 683 | 1948 | 269 | 24 | 7 | 743 |
| Ticagrelor - Stage IIb | 171 | 560 | 469 | 12 | 5 | 403 |
| Ticagrelor - Stage III | 15 | 41 | 39 | 31 | 1 | 59 |
| Ticagrelor - Stage IV | 26 | 28 | 19 | 7 | 13 | 47 |
"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Category 0 - End of treatment | Category 1/2 - End of treatment | Category 3 - End of treatment | Category 4 - End of treatment | Category 5 - End of treatment | Category 6 - End of treatment | Missing - End of treatment | |
| Clopidogrel - Cat 0 | 743 | 230 | 56 | 9 | 2 | 2 | 250 |
| Clopidogrel - Cat 1/2 | 723 | 1956 | 311 | 15 | 6 | 1 | 724 |
| Clopidogrel - Cat 3 | 198 | 557 | 450 | 23 | 6 | 4 | 370 |
| Clopidogrel - Cat 4 | 33 | 33 | 38 | 23 | 4 | 1 | 60 |
| Clopidogrel - Cat 5 | 13 | 18 | 12 | 11 | 12 | 0 | 34 |
| Clopidogrel - Cat 6 | 6 | 3 | 3 | 1 | 1 | 0 | 11 |
| Ticagrelor - Cat 0 | 775 | 227 | 45 | 7 | 5 | 2 | 248 |
| Ticagrelor - Cat 3 | 171 | 560 | 469 | 12 | 3 | 2 | 403 |
| Ticagrelor - Cat 4 | 15 | 41 | 39 | 31 | 1 | 0 | 59 |
| Ticagrelor - Cat 5 | 23 | 23 | 13 | 4 | 11 | 0 | 33 |
| Ticagrelor - Cat 6 | 3 | 5 | 6 | 3 | 0 | 2 | 14 |
| Ticagrelor - Stage II | 683 | 1948 | 269 | 24 | 4 | 3 | 743 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | pariticipants (Number) |
|---|---|
| Cilostazol | 34 |
| Clopidogrel | 23 |
including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 15 |
| Clopidogrel | 10 |
"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 20 |
| Clopidogrel | 32 |
including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 11 |
| Clopidogrel | 7 |
ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 9 |
| Clopidogrel | 5 |
life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | events (Number) |
|---|---|
| Cilostazol | 2 |
| Clopidogrel | 6 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
24 reviews available for ticlopidine and Ischemia
| Article | Year |
|---|---|
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
Topics: Adult; Aspirin; Cause of Death; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Ische | 2018 |
Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Dr | 2013 |
Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol.
Topics: Cilostazol; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; End | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Drug Therapy, Com | 2008 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Resistance; Endothelium, Vascular; Humans; Ischemia; O | 2009 |
Platelet function testing and implications for clinical practice.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl | 2009 |
[Medicinal therapy for interventional surgery of the peripheral vascular system].
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Therap | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; | 2011 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; | 2013 |
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug | 2013 |
Antiplatelet agents in atherothrombotic diseases.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Platelet Aggregation Inhibit | 2004 |
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med | 2004 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; D | 2008 |
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com | 2008 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Adjuvant medical therapy in peripheral bypass surgery.
Topics: Alprostadil; Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dextrans; Do | 1999 |
22 trials available for ticlopidine and Ischemia
| Article | Year |
|---|---|
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Ka | 2018 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery.
Topics: Aged; Anticoagulants; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Endovascular | 2013 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.
Topics: Aged; Asian People; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Constriction, Pathologic; Cyt | 2016 |
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2017 |
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidog | 2009 |
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; | 2010 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor | 2010 |
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platelet | 2010 |
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou | 2011 |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot | 2012 |
Increased local cytokine production at culprit superficial femoral artery plaques.
Topics: Aspirin; CD40 Ligand; Clopidogrel; Constriction, Pathologic; Female; Femoral Artery; Humans; Hydroxy | 2013 |
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Coronary Disea | 2005 |
Therapeutic effect of ticlopidine for ischemic leg ulcers.
Topics: Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Female; Humans; Ischemia; Leg | 1984 |
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Double-Bli | 1982 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Double-Blind Method; Female; Hospitalization; Hum | 2001 |
[Application of preparation endotelon in complex treatment of chronic arterial insufficiency of lower extremities].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arterial Occlusive Diseases; Aspirin; Biflavo | 2000 |
47 other studies available for ticlopidine and Ischemia
| Article | Year |
|---|---|
Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Haplotypes; Humans; Ischemia; Pakistan; Platelet Ag | 2022 |
Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combinatio | 2017 |
Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Greece; | 2017 |
The association between clopidogrel and 2-oxo-clopidogrel plasma levels and the long-term clinical outcome after acute myocardial infarction
.
Topics: Clopidogrel; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet A | 2019 |
Platelet antiaggregation therapy and subinguinal endovascular revascularization.
Topics: Aged; Aged, 80 and over; Clopidogrel; Endovascular Procedures; Humans; Ischemia; Lower Extremity; Me | 2013 |
Why have studies of tailored anti-platelet therapy failed so far?
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Humans; Ische | 2013 |
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.
Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage | 2014 |
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Base Sequence; Cilostazol; Clopidogrel; DNA Pr | 2014 |
Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup.
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; C | 2015 |
High on-treatment platelet reactivity in transcatheter aortic valve implantation patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Ischemia; Male; Platelet Aggregation In | 2015 |
Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.
Topics: Aged; Aged, 80 and over; Area Under Curve; Aspirin; Clopidogrel; Critical Illness; Drug Resistance; | 2014 |
Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.
Topics: Adenosine Diphosphate; Adult; Aged; Alleles; Blood Coagulation; Blood Platelets; China; Clopidogrel; | 2015 |
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases; | 2015 |
Platelet reactivity in MitraClip patients.
Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit | 2016 |
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
Topics: Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Humans; Ischemia; Male; | 2016 |
Dual Antiplatelet Therapy in the Prevention of Recurrent Ischemic Events.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemia; Platelet Aggregation Inhibitor | 2016 |
Impact of different antithrombotics on the microcirculation and viability of perforator-based ischaemic skin flaps in a small animal model.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Graft Survival; Heparin; | 2016 |
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic | 2017 |
Radiocephalic fistula complicated by distal ischemia: treatment by ulnar artery dilatation.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Catheters, Indwelling; Clopidogrel; Diabete | 2010 |
Aortic thromboembolism successfully treated with anticoagulation and antiplatelet therapy.
Topics: Anticoagulants; Aorta, Thoracic; Arm; Clopidogrel; Coronary Artery Disease; Echocardiography, Transe | 2009 |
Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Humans; Ische | 2010 |
Endovascular management of patients with critical limb ischemia.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Boston; Clopidogrel; Critical I | 2011 |
[Preoperative analysis of platelet aggregability in carotid surgery].
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Clopidogrel; Endarterectomy, Carotid; Female; Hu | 2011 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aspirin; Female; Humans; Ischemia; Leg; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Reply to letter: "Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia".
Topics: Aspirin; Female; Humans; Ischemia; Leg; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response | 2012 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi | 2012 |
Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia.
Topics: Animals; Blotting, Western; Cilostazol; Clopidogrel; Drug Therapy, Combination; Extremities; Flow Cy | 2012 |
Influence of ischemia before vein grafting on early hyperplasia of the graft and the dynamic changes of the intima after grafting.
Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cell Proliferation; Clopidog | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
Acute peripheral arterial ischemia and suspected aortic dissection: usefulness of transesophageal echocardiography in differential diagnosis with aortic thrombosis.
Topics: Acute Disease; Adult; Aged; Amputation, Surgical; Anticoagulants; Aortic Diseases; Arterial Occlusiv | 2002 |
Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia.
Topics: Animals; Clopidogrel; Disease Models, Animal; Glutathione; Ischemia; Male; Malondialdehyde; Oxidants | 2005 |
Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections.
Topics: Adult; Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis I | 2005 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochro | 2005 |
CHARISMA: the antiplatelet saga continues.
Topics: Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Platelet Aggregation Inhib | 2006 |
Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state.
Topics: Aged; Aged, 80 and over; Antithrombin III; Arterial Occlusive Diseases; Aspirin; Blood Coagulation; | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Clopidogrel-induced spontaneous spinal epidural hematoma.
Topics: Aged; Brain; Cerebral Angiography; Clopidogrel; Female; Hematoma, Epidural, Spinal; Humans; Ischemia | 2007 |
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Acute Disease; Adenosine Diphosphate; Aged; Blood Platelets; Cell Adhesion | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem | 2007 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease.
Topics: Aged; Blood Gas Monitoring, Transcutaneous; Drug Evaluation; Female; Gangrene; Humans; Intermittent | 1993 |
Aspirin versus clopidogrel: the wrong question?
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet A | 1997 |
Clopidogrel: a novel antiplatelet agent.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre | 1999 |
Hereditary hemorrhagic telangiectasia, factor V Leiden and antiphospholipid syndrome: a case report.
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Autoantibodies; Factor V; Female; Humans; Is | 2002 |
[Validation of an automatic quantification system in angiography. Research group studying ticlopidine in atherosclerosis of the lower leg].
Topics: Angiography; Arteriosclerosis; Femoral Artery; Humans; Iliac Artery; Ischemia; Leg; Models, Cardiova | 1989 |